Activities of Daily Living
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Aged
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Aged, 80 and over
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Alzheimer Disease
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Amyloid beta-Peptides
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Antibodies, Monoclonal, Humanized
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Apolipoproteins E
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.